Interpretation and inference in noninferiority randomized controlled trials in drug research

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 3, 2010, Pages 420-423

  Wangge, G ^a   Klungel, O H ^a   Roes, K C B ^b   De Boer, A ^a   Hoes, A W ^b   Knol, M J ^a,b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG; PLACEBO;

CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

DATA INTERPRETATION, STATISTICAL; HUMANS; PHARMACEUTICAL PREPARATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; THERAPEUTIC EQUIVALENCY;

EID: 77955920451     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.134     Document Type: Review

References (17)

1. Hung, H.M., Wang, S.J. & O'Neill, R. A regulatory perspective on choice of margin and statistical inference issue in non-inferiority trials. Biom. J. 47, 28-36; discussion 99 (2005).
2. D'Agostino, R.B. sr, Massaro, J.M. & Sullivan, L.M. Non-inferiority trials: design concepts and issues-the encounters of academic consultants in statistics. Stat. Med. 22, 169-186 (2003).
3. Garattini, S. & Bertele', V. Non-inferiority trials are unethical because they disregard patients' interests. Lancet 370, 1875-1877 (2007)
4. CDER, CBER. Draft Guidance: Guidance for Industry Non-Inferiority Clinical trials (2010).
5. Snapinn, S.M. Alternatives for discounting in the analysis of noninferiority trials. J. Biopharm. Stat. 14, 263-273 (2004).
6. Hung, H.M.J., Sue-Jane, W., Robert, O.N. Challenges and regulatory experiences with non-inferiority trial design without placebo arm. Biom. J. 51, 324-334 (2009).
7. CHMp. Guideline on the choice of the non-inferiority margin. In EMEa, Vol EMEA/CpMp/EWp/2158/99 (EMEA, 2005).
8. Cooper, C. et al. Efcacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 88, 4609-4615 (2003).
9. ICH. stastistical principles for clinical trials\E9. In Use ICOHOTRFROPFH (ICH Expert Working Group, 1998).
10. ICH. E10: Choice of control group and related issues in clinical trials. In Use ICOHOTRFROPFH (ICH Expert Working Group, 2001).
11. CpMp. points to consider on switching between superiority and non-inferiority. In EMEA, Vol CpMp/EWp/482/99 (EMEA, 2000).
12. Snapinn, S.M. Noninferiority trials. Curr. Control. Trials Cardiovasc. Med. 1, 19-21 (2000).
13. Kay, R. Equivalence and non-inferiority. In Statistical Thinking for Non-Statisticians in Drug Regulation (ed. Kay, R.) 173-191 (Wiley, Derbyshire, UK, 2007).
14. Senn, S. Active control equivalence studies. statistical Issues in Drug Development, 2nd edn (ed. senn, S.) 235-247 (Wiley, Glasgow, UK, 2007).
15. McMahon, R.P. et al. Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research. Schizophr. Bull. 34, 292-301 (2008).
16. Britton, M. Bayesian Approach To Three-Arm Non-Inferiority Trials. (College of Arts and sciences, Georgia state University, 2007).
17. Piaggio, G., Elbourne, D.R., Altman, D.G., Pocock, S.J. & Evans, S.J.; CONsORt Group. Reporting of noninferiority and equivalence randomized trials: an extension of the CONsORt statement. JAMA 295, 1152-1160 (2006).